Jane Huang

8.6k total citations · 1 hit paper
90 papers, 4.2k citations indexed

About

Jane Huang is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Jane Huang has authored 90 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Genetics, 38 papers in Pathology and Forensic Medicine and 17 papers in Oncology. Recurrent topics in Jane Huang's work include Chronic Lymphocytic Leukemia Research (53 papers), Lymphoma Diagnosis and Treatment (37 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Jane Huang is often cited by papers focused on Chronic Lymphocytic Leukemia Research (53 papers), Lymphoma Diagnosis and Treatment (37 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Jane Huang collaborates with scholars based in United States, China and Australia. Jane Huang's co-authors include Thomas J. Marrie, James J. Vredenburgh, Randy L. Jensen, Lauren E. Abrey, Henry S. Friedman, Tom Mikkelsen, Michael D. Prados, Timothy F. Cloughesy, M. Kelly Nicholas and David Schiff and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jane Huang

85 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

2009 1.9k citations Henry S. Friedman, Michael D. Prados et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane Huang United States	25	2.3k	1.1k	999	910	716	90	4.2k
Maya H Buch United Kingdom	42	996 0.4×	658 0.6×	575 0.6×	1.1k 1.2×	560 0.8×	211	6.4k
Roy B. Jones United States	43	1.2k 0.5×	765 0.7×	2.5k 2.5×	735 0.8×	970 1.4×	176	6.6k
Kirk R. Schultz Canada	45	1.1k 0.5×	631 0.6×	1.3k 1.3×	407 0.4×	770 1.1×	214	7.4k
Jean-Philippe Jaı̈s France	36	543 0.2×	566 0.5×	1.2k 1.2×	1.3k 1.5×	1.3k 1.8×	138	4.8k
Roberto Stasi Italy	49	1.9k 0.8×	1.1k 1.0×	1.1k 1.1×	1.9k 2.1×	940 1.3×	161	9.7k
Pia Raanani Israel	35	920 0.4×	338 0.3×	878 0.9×	669 0.7×	1.0k 1.4×	305	4.2k
Lingyun Ji United States	34	587 0.3×	720 0.7×	944 0.9×	366 0.4×	828 1.2×	130	3.5k
Vincent Audard France	35	635 0.3×	980 0.9×	1.2k 1.2×	489 0.5×	906 1.3×	182	4.8k
Michael A. Pulsipher United States	47	1.3k 0.6×	361 0.3×	2.4k 2.4×	902 1.0×	1.1k 1.5×	253	7.6k
Michael Dworzak Austria	45	654 0.3×	416 0.4×	1.2k 1.2×	541 0.6×	1.2k 1.7×	189	5.8k

Countries citing papers authored by Jane Huang

Since Specialization

Citations

This map shows the geographic impact of Jane Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Huang more than expected).

Fields of papers citing papers by Jane Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Huang. The network helps show where Jane Huang may publish in the future.

Co-authorship network of co-authors of Jane Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Huang. A scholar is included among the top collaborators of Jane Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Huang. Jane Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Jane, Philippe Friedlich, & Molly C. Easterlin. (2024). Does early prostacyclin therapy decrease extracorporeal life support use in infants with congenital diaphragmatic hernia?. Journal of Perinatology. 44(4). 594–597.

Jiang, Yuanyuan, et al.. (2024). Developing scalable hands-on virtual and mixed-reality science labs. Virtual Reality. 28(4).

Soumerai, Jacob D., Catherine Diefenbach, Adam Asch, et al.. (2024). Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. British Journal of Haematology. 204(5). 1762–1770. 3 indexed citations

Huang, Jane, et al.. (2024). SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS. Inflammatory Bowel Diseases. 30(Supplement_1). S82–S83.

Whitten, Tara A., et al.. (2023). Impact of Health Link utilization on emergency department visits. Canadian Journal of Emergency Medicine. 25(5). 429–433. 3 indexed citations

Tam, Constantine S., Stephen Opat, David Simpson, et al.. (2021). Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances. 5(12). 2577–2585. 63 indexed citations

Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations

Huang, Jane, et al.. (2020). Effect of high nucleated cell concentration on product viability and hematopoietic recovery in autologous transplantation. Transfusion. 60(3). 575–581. 2 indexed citations

Trotman, Judith, Stephen Opat, David Gottlieb, et al.. (2020). Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 136(18). 2027–2037. 73 indexed citations

10.

Hillmen, Peter, Jennifer R. Brown, John C. Byrd, et al.. (2019). Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 134(Supplement_1). 4307–4307. 2 indexed citations

11.

Tremblay, Alain, Niloofar Taghizadeh, Jane Huang, et al.. (2019). A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program. Journal of Thoracic Oncology. 14(9). 1528–1537. 41 indexed citations

12.

Zhu, Jun, Jianyong Li, Jianfeng Zhou, et al.. (2017). BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China. Blood. 130. 5347–5347. 3 indexed citations

13.

Tam, Constantine S., Hang Quach, Andrew J. Nicol, et al.. (2017). BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma. Blood. 130. 1745–1745. 1 indexed citations

14.

Cull, Gavin, Stephen Opat, Judith Trotman, et al.. (2017). Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies. Blood. 130. 4057–4057. 2 indexed citations

15.

Othman, Jad, Emma Verner, Constantine S. Tam, et al.. (2017). Autoimmune hemolytic anemia and hemolytic transfusion reactions in two patients with Waldenstrom macroglobulinemia treated with combination BTK inhibitor and PD-1 inhibitor. Blood. 130. 5153–5153. 1 indexed citations

16.

Chuang, Jody C., Henning Stehr, Ying Liang, et al.. (2017). ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology. 12(5). 833–842. 60 indexed citations

17.

Friedman, Henry S., Michael D. Prados, Patrick Y. Wen, et al.. (2009). Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 27(28). 4733–4740. 1855 indexed citations breakdown →

18.

Ahmed, Rabia, Thomas J. Marrie, & Jane Huang. (2006). Thoracic Empyema in Patients with Community-Acquired Pneumonia. The American Journal of Medicine. 119(10). 877–883. 117 indexed citations

19.

Marrie, Thomas J. & Jane Huang. (2005). Community‐Acquired Pneumonia in Patients Receiving Home Care. Journal of the American Geriatrics Society. 53(5). 834–839. 8 indexed citations

20.

Basi, Sanraj, Thomas J. Marrie, Jane Huang, & Sumit R. Majumdar. (2004). Patients admitted to hospital with suspected pneumonia and normal chest radiographs: Epidemiology, microbiology, and outcomes. The American Journal of Medicine. 117(5). 305–311. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact